Compare General Mills, Inc. (GIS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? General Mills, Inc. trades at $32.5 (market cap $17.17B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: General Mills, Inc. is far larger — about 3.4× Travere Therapeutics Inc. Common Stock's market cap, and General Mills, Inc. pays a 7.6% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GIS | TVTX | |
|---|---|---|
Market Cap | $17.17B | $5.02B |
Volume | 12,286,564 | 2,060,842 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $67.52 |
52-Week Low | $31.67 | $26.79 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.35B | $5.15B |
Dividend Yield | 7.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.83, down 2.66% amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with a recent Q2 beat but Q4 miss, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. Analyst consensus remains cautious with 61% hold ratings, though the $36 price target suggests 13% upside potential. Recent CEO transition and dividend declaration provide stability signals despite profitability challenges.
The outlook remains challenged by declining margins and negative ROE/ROA, though attractive valuation (P/E 9.2) and dividend yield offer value appeal. Key risks include continued revenue pressure, margin compression, and high debt levels at 45% of assets. Upside depends on successful execution of the $3B savings plan and international growth initiatives.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
